Diagnostic and therapeutic agents for rheumatoid arthritis
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsYoshimi Homma, Koichiro Sato
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic agent for rheumatoid arthritis which inhibits the growth of synoviocytes mediated by c-erbB-2 by clarifying the participation of c-erbB-2 in the growth of synoviocytes in rheumatoid arthritis patients and inhibiting the activation or expression of c-erbB-2.
Claims19
A method for treating rheumatoid arthritis, comprising
- administering to a patient in need thereof an effective amount of a neutralizing antibody or binding fragment thereof, wherein said neutralizing antibody or binding fragment binds specifically to c-erb-B2.
2-5. (canceled)
A method for treating rheumatoid arthritis, comprising
- administering to a patient in need thereof an effective amount of a substance which inhibits the binding of an erbB ligand to c-erbB-2 or which inhibits the binding of an erbB ligand to a receptor comprising c-erbB-2, wherein said substance binds to an erbB ligand and inhibits the binding of the erbB ligand to c-erbB-2 or a receptor forming a heteroreceptor with c-erbB-2.
(canceled)
A method for treating rheumatoid arthritis comprising
- administering to a patient in need thereof an effective amount of a substance which inhibits the signal transduction after the binding of an erbB ligand toc-erbB-2, wherein said substance inhibits the tyrosine phosphorylation of c-erbB-2 or inhibits the interaction between phosphorylated c-erbB-2 and an intracellular signaling molecule.
A method for treating rheumatoid arthritis, comprising administering to a patient in need thereof an effective amount of a substance which suppresses the expression of c-erbB-2 selected from the group consisting of antisense DNAs, antisense oligonucleotides, triple helix-forming oligonucleotides and ribozymes for the c-erbB-2 gene.
A method for inhibiting synoviocyte growth, comprising administering to a patient an effective amount of a neutralizing antibody or binding fragment thereof that binds specifically to a c-erb-B2.
14-17. (canceled)
A method for inhibiting synoviocyte growth, comprising
- administering to a patient in need thereof an effective amount of a substance which inhibits the binding of an erbB ligand to c-erbB-2 or inhibits the binding of an erbB ligand to a receptor comprising c-erbB-2, wherein said substance binds to and forms a heteroreceptor with c-erbB-2.
A method for inhibiting synoviocyte growth, comprising:
- administering to a patient in need thereof an effective amount of an antagonist of c-erbB-2 or receptors forming heteroreceptors with c-erbB-2, wherein said antagonists are neutralizing antibodies a fragment of said antibodies, or derivatives thereof.
A method for inhibiting synoviocyte growth, comprising
- administering to a patient in need thereof a substance which inhibits the signal transduction after the binding of an erbB ligand to c-erbB-2 wherein said substance inhibits the tyrosine phosphorylation of c-erbB-2 or inhibits the interaction between phosphorylated c-erbB-2 and an intracellular signaling molecule.
A method for inhibiting synoviocyte growth, comprising administering to a patient in need thereof an effective amount of a substance which inhibits the expression of c-erbB-2 selected from the group consisting of antisense DNAs, antisense oligonucleotides, triple helix-forming oligonucleotides and ribozymes for the c-erbB-2 gene.
25-27. (canceled)
Dependencies are inferred from the claim text.